Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Sees Turnaround With Urology, Transplantation And Oncology Products

This article was originally published in PharmAsia News

Executive Summary

Astellas has rolled out a five-year management plan to bounce back from patent expiries and declining sales; and fresh off a long-fought bid for OSI Pharmaceuticals, the company expects oncology to bolster growth driven by its core therapeutic competencies of urology and transplantation

You may also be interested in...



Astellas Completes OSI Acquisition; Shares Jump In Tokyo

Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding

Astellas Completes OSI Acquisition; Shares Jump In Tokyo

Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding

Astellas Wins OSI But Victory Comes At A Price

Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17, 2010 with a definitive merger agreement that has the unanimous support of both companies' boards. The victory cost $4 billion, about $500 million more than the original hostile bid which Astellas launched in late February ("The Pink Sheet" DAILY, March 1, 2010)

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel